Segment Wealth Management LLC Has $12.27 Million Stake in Zoetis Inc. (NYSE:ZTS)

Segment Wealth Management LLC grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.9% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 75,320 shares of the company’s stock after purchasing an additional 654 shares during the period. Segment Wealth Management LLC’s holdings in Zoetis were worth $12,272,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pensionfund Sabic raised its position in Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after buying an additional 4,000 shares during the last quarter. PFW Advisors LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at about $1,764,000. JPMorgan Chase & Co. lifted its position in shares of Zoetis by 10.6% during the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after purchasing an additional 279,092 shares in the last quarter. Simplify Asset Management Inc. bought a new position in shares of Zoetis during the third quarter valued at about $11,684,000. Finally, B&L Asset Management LLC purchased a new position in Zoetis during the third quarter worth about $563,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. UBS Group began coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $211.89.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $166.01 on Tuesday. The company has a 50-day moving average price of $170.93 and a two-hundred day moving average price of $180.01. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $74.90 billion, a PE ratio of 31.20, a P/E/G ratio of 2.55 and a beta of 0.89.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.36 EPS. Equities analysts forecast that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a $0.50 dividend. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 annualized dividend and a yield of 1.20%. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio (DPR) is currently 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.